Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. AMC
4. MSFT
5. ACN
6. FFAI
7. WBD
8. OKTA
9. STI
10. AMZN

Go back to Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
Johnson & Johnson (NYSE: JNJ) Delayed: 269.99 --0 (-0%)
Previous Close $269.99    52 Week High $126.07 
Open $269.99    52 Week Low $94.28 
Day High $269.99    P/E 56.13 
Day Low $269.99    EPS $4.81 
Volume 11,724